Share This Link

Morphine is a potent opioid analgesic commonly prescribed for moderate to severe pain. A dosage of 4 mg intravenously every four hours as needed for pain is within the typical therapeutic range for post-operative pain management, and the frequency allows for sufficient time between doses to assess the analgesic effect and minimize accumulation.

Ondansetron is a serotonin receptor antagonist used to prevent and treat nausea and vomiting. A dosage of 4 mg orally every eight hours as needed for nausea is a standard and safe therapeutic dose, commonly employed in the post-operative setting to manage emesis with minimal adverse effects.

Docusate sodium is a stool softener that works by increasing water and fat penetration into the stool, making it easier to pass. A dosage of 240 mg orally daily as needed for constipation is a common and appropriate dose for preventing and managing post-operative constipation, which is a frequent side effect of opioid analgesics.

Disulfiram is an aldehyde dehydrogenase inhibitor used in the treatment of chronic alcoholism. It works by blocking the metabolism of ethanol, leading to the accumulation of acetaldehyde, which produces unpleasant physical reactions when alcohol is consumed. It has no pharmacological effect on benzodiazepine overdose.

Naloxone is an opioid receptor antagonist primarily used to reverse opioid overdose. It competitively binds to opioid receptors, particularly mu receptors, thereby blocking the effects of opioid agonists and reversing respiratory depression and other opioid-induced central nervous system depression. It does not affect benzodiazepines.

Dantrolene is a direct-acting skeletal muscle relaxant primarily used in the treatment of malignant hyperthermia and spasticity. It works by interfering with calcium release from the sarcoplasmic reticulum in muscle cells, reducing muscle contraction. It has no role in reversing benzodiazepine overdose.

A prothrombin time (PT) of 15.5 seconds, while slightly above the normal range of 11 to 12.5 seconds, indicates a mild prolongation of clotting time. For a client on warfarin, a slight elevation in PT is often expected as it reflects the anticoagulant effect. This value alone may not necessitate immediate reporting.

An activated partial thromboplastin time (aPTT) of 45 seconds, slightly above the normal range of 30 to 40 seconds, indicates a minor prolongation in the intrinsic and common pathways of coagulation. While relevant for heparin therapy, its direct significance for warfarin's primary monitoring is less critical.

A platelet count of 90,000/mcL is below the normal range of 150,000 to 400,000/mcL, indicating thrombocytopenia. While important for hemostasis, warfarin primarily affects clotting factors, not platelet production. However, a low platelet count combined with high INR further increases bleeding risk, necessitating reporting.

An increased serum bilirubin level can indicate liver dysfunction, which is a potential adverse effect of cyclosporine. However, without specific values or other symptoms, this finding alone might not be an immediate emergency, though it warrants further investigation to assess liver health. Normal total bilirubin is 0.3 to 1.2 mg/dL.

Hair growth (hirsutism) is a common and recognized side effect of cyclosporine therapy, particularly in women. While it can be bothersome cosmetically, it is generally not indicative of an immediate or life-threatening adverse event and does not require urgent reporting.

A blood pressure of 128/82 mm Hg is slightly elevated but generally considered within an acceptable range, although on the higher side of normal. Cyclosporine can cause hypertension, but this specific reading does not represent a hypertensive crisis or an immediate emergency requiring urgent intervention.

Distribution refers to the reversible movement of a drug from the systemic circulation to the body's tissues. While food can indirectly influence distribution by altering blood flow or protein binding, its primary and most direct impact on drug pharmacokinetics is not typically on the distribution phase itself.

Metabolism, primarily occurring in the liver, involves the biochemical modification of drugs. While some foods can induce or inhibit metabolic enzymes, the direct and immediate effect of the presence of food at the time of administration is typically not on the rate of drug metabolism but rather on the initial entry into the systemic circulation.

Excretion is the elimination of drugs from the body, mainly through the kidneys. Food generally does not directly influence the rate of drug excretion, which is primarily dependent on renal function, glomerular filtration, tubular secretion, and reabsorption processes.

Restlessness, also known as akathisia, is not a typical expected adverse effect of ondansetron. Ondansetron primarily acts as a selective 5-HT3 receptor antagonist, blocking serotonin's emetogenic effects in the chemoreceptor trigger zone and gastrointestinal tract. Common adverse effects are generally mild, including headache, constipation, or diarrhea, with neurological effects like restlessness being rare and atypical for this drug's primary mechanism.

Ondansetron should be administered prophylactically, typically 30 minutes *before* chemotherapy, to achieve optimal antiemetic effect. Its mechanism involves blocking serotonin receptors that, when activated by chemotherapy, trigger nausea and vomiting. Pre-emptive administration ensures therapeutic drug levels are present to counteract the emetogenic stimuli effectively before their onset.

Acute nausea and vomiting associated with chemotherapy can persist for significantly longer than 12 hours, often lasting for 24 to 48 hours or even longer depending on the specific chemotherapeutic agent and its emetogenic potential. The duration of emesis is highly variable and directly related to the drug's pharmacokinetic profile and the extent of serotonin release.

Delegating medication administration to an assistive personnel (AP) is inappropriate as medication administration is a complex nursing function requiring assessment, judgment, and patient education, which are outside the scope of practice for an AP. An AP's role is typically limited to basic care activities, and they are not trained or authorized to administer medications.

Notifying the pharmacist is not the immediate or primary action when a client refuses medication. While the pharmacist may offer insights into alternative formulations or administration routes, the nurse's initial responsibility is to understand the client's refusal, document it, and then notify the prescribing provider for a revised plan of care.

Mixing medication in juice without the client's explicit consent is considered a breach of the client's autonomy and can be construed as coercive or deceptive. It violates the client's right to self-determination and informed consent regarding their treatment. Medications should only be administered with the client's knowledge and cooperation.

Constipation is a very common and expected adverse effect of codeine due to its opioid effects on gastrointestinal motility, specifically by decreasing propulsive contractions. While it requires management, it is generally not the highest priority unless it leads to severe complications like impaction, making other acute symptoms more immediately concerning. Normal bowel frequency varies but ranges from three times daily to three times weekly.

Dry mouth, or xerostomia, is a common anticholinergic-like effect of opioid medications like codeine. While uncomfortable, it is typically a mild, non-life-threatening side effect. It can be managed with hydration and oral hygiene measures and does not represent an acute physiological threat requiring immediate reporting as a priority.

Urinary retention is a known adverse effect of opioids due to their effect on bladder detrusor muscle tone and sphincter function. While it is important to monitor and manage, potentially requiring catheterization, it is generally not as immediately life-threatening as signs of central nervous system instability or respiratory compromise, making agitation a higher priority in the acute setting.

Administering aspirin for fever in a client receiving alteplase is contraindicated. Alteplase is a potent thrombolytic, and aspirin, an antiplatelet agent, would significantly increase the risk of bleeding. If fever is present, acetaminophen would be the preferred antipyretic due to its lack of antiplatelet activity, minimizing the risk of hemorrhage in this high-risk patient.

Ambulation is contraindicated in a client receiving thrombolytic therapy. Alteplase lyses existing clots, increasing the risk of bleeding, especially from sites of trauma or increased pressure. Maintaining bed rest and limiting movement helps to minimize the risk of hemorrhagic complications, such as hematoma formation or internal bleeding, which could be exacerbated by physical activity.

Administering a sodium phosphate enema is contraindicated in a client receiving thrombolytic therapy. Sodium phosphate enemas can cause rectal irritation, mucosal injury, and increased peristalsis, all of which elevate the risk of gastrointestinal bleeding in a patient whose coagulation cascade is already significantly impaired by alteplase. Stool softeners are preferred if constipation is present.

Aspartate aminotransferase (AST) is an enzyme primarily found in the liver, heart, and muscle. Elevated levels can indicate hepatocellular damage or cardiac muscle injury. While some medications can affect liver function, AST is not a primary monitoring parameter for methylprednisolone, which is a corticosteroid, unless specific hepatotoxicity is suspected or pre-existing liver conditions exist. Normal AST levels are typically 10-40 U/L.

Fibrin split products (FSPs) are indicators of fibrinolysis, the breakdown of fibrin clots. Elevated FSPs suggest active clotting and subsequent clot degradation, often seen in disseminated intravascular coagulation (DIC). Methylprednisolone, a corticosteroid, does not directly impact fibrinolysis or coagulation to warrant routine monitoring of FSPs as a primary concern. This test is not routinely indicated.

Blood urea nitrogen (BUN) measures the amount of nitrogen in the blood that comes from the waste product urea. Elevated BUN can indicate kidney dysfunction or dehydration. While corticosteroids can influence fluid balance, BUN is not a specific or primary laboratory value monitored for the direct effects of methylprednisolone therapy unless a pre-existing renal impairment is present. Normal BUN levels are typically 7-20 mg/dL.